Fluoropyrimidine‑induced cardiotoxicity in colorectal cancer patients : a prospective observational trial (CHECKPOINT)
Fluoropyrimidines (FP) are the backbone chemotherapy in colorectal cancer (CRC) treatment; however, their use is associated with cardiotoxicity, which is underreported. In the present study, it was aimed to prospectively determine the incidence rates and related risk factors of FP‑induced cardiotoxicity (FIC) in CRC patients and at identifying predictive biomarkers. A total of 129 consecutive previously untreated CRC patients underwent active cardiological monitoring, including 5‑items simplified questionnaire on symptoms, electrocardiogram (ECG) and plasma sample collection during FP chemotherapy. FIC was defined as the presence of ECG alterations and/or the arising of at least one symptom of chest pain, dyspnoea, palpitations or syncope. The primary objective was the evaluation of FIC incidence. Secondary objectives were the correlation of FIC with well‑known cardiological risk factors and the identification of circulating biomarkers (serum levels of troponin I, pro hormone BNP; miRNA analysis) as predictors of FIC. A total of 20 out of 129 (15.5%) patients experienced FIC. The most common symptoms were dyspnoea (60%) and chest pain (40%), while only 15% of patients presented ECG alterations, including one acute myocardial infarction. Retreatment with FP was attempted in 90% of patients with a favourable outcome. Despite 48% of patients having cardiological comorbidities, an increased FIC was not observed in this subgroup. Only the subgroup of females with the habit of alcohol consumption showed an increased risk of FIC. None of the circulating biomarkers evaluated demonstrated a clinical utility as FIC predictors. FIC can be an unexpected, life‑threatening adverse event that can limit the subsequent treatment choices in patients with CRC. In this prospective study, well‑known cardiological comorbidities were not related to higher FIC risk and circulating biomarkers predictive of toxicity could not be found. With careful monitoring, mainly based on symptoms, almost all patients completed the FP treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
Oncology reports - 49(2023), 2 vom: 23. Feb. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Lombardi, Pasquale [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antimetabolites |
|---|
| Anmerkungen: |
Date Completed 26.12.2022 Date Revised 15.01.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3892/or.2022.8468 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM350738998 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM350738998 | ||
| 003 | DE-627 | ||
| 005 | 20231226045656.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3892/or.2022.8468 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1169.xml |
| 035 | |a (DE-627)NLM350738998 | ||
| 035 | |a (NLM)36562382 | ||
| 035 | |a (PII)31 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Lombardi, Pasquale |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Fluoropyrimidine‑induced cardiotoxicity in colorectal cancer patients |b a prospective observational trial (CHECKPOINT) |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.12.2022 | ||
| 500 | |a Date Revised 15.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Fluoropyrimidines (FP) are the backbone chemotherapy in colorectal cancer (CRC) treatment; however, their use is associated with cardiotoxicity, which is underreported. In the present study, it was aimed to prospectively determine the incidence rates and related risk factors of FP‑induced cardiotoxicity (FIC) in CRC patients and at identifying predictive biomarkers. A total of 129 consecutive previously untreated CRC patients underwent active cardiological monitoring, including 5‑items simplified questionnaire on symptoms, electrocardiogram (ECG) and plasma sample collection during FP chemotherapy. FIC was defined as the presence of ECG alterations and/or the arising of at least one symptom of chest pain, dyspnoea, palpitations or syncope. The primary objective was the evaluation of FIC incidence. Secondary objectives were the correlation of FIC with well‑known cardiological risk factors and the identification of circulating biomarkers (serum levels of troponin I, pro hormone BNP; miRNA analysis) as predictors of FIC. A total of 20 out of 129 (15.5%) patients experienced FIC. The most common symptoms were dyspnoea (60%) and chest pain (40%), while only 15% of patients presented ECG alterations, including one acute myocardial infarction. Retreatment with FP was attempted in 90% of patients with a favourable outcome. Despite 48% of patients having cardiological comorbidities, an increased FIC was not observed in this subgroup. Only the subgroup of females with the habit of alcohol consumption showed an increased risk of FIC. None of the circulating biomarkers evaluated demonstrated a clinical utility as FIC predictors. FIC can be an unexpected, life‑threatening adverse event that can limit the subsequent treatment choices in patients with CRC. In this prospective study, well‑known cardiological comorbidities were not related to higher FIC risk and circulating biomarkers predictive of toxicity could not be found. With careful monitoring, mainly based on symptoms, almost all patients completed the FP treatment | ||
| 650 | 4 | |a Observational Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a cardioncologist | |
| 650 | 4 | |a colorectal cancer | |
| 650 | 4 | |a fluoropyrimidines‑induced cardiotoxicity | |
| 650 | 7 | |a Antimetabolites |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 700 | 1 | |a Aimar, Giacomo |e verfasserin |4 aut | |
| 700 | 1 | |a Peraldo-Neia, Caterina |e verfasserin |4 aut | |
| 700 | 1 | |a Bonzano, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Depetris, Ilaria |e verfasserin |4 aut | |
| 700 | 1 | |a Fenocchio, Elisabetta |e verfasserin |4 aut | |
| 700 | 1 | |a Filippi, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Quarà, Virginia |e verfasserin |4 aut | |
| 700 | 1 | |a Milanesio, Michela |e verfasserin |4 aut | |
| 700 | 1 | |a Cavalloni, Giuliana |e verfasserin |4 aut | |
| 700 | 1 | |a Gammaitoni, Loretta |e verfasserin |4 aut | |
| 700 | 1 | |a Basiricò, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Cagnazzo, Celeste |e verfasserin |4 aut | |
| 700 | 1 | |a Ostano, Paola |e verfasserin |4 aut | |
| 700 | 1 | |a Chiorino, Giovanna |e verfasserin |4 aut | |
| 700 | 1 | |a Aglietta, Massimo |e verfasserin |4 aut | |
| 700 | 1 | |a Leone, Francesco |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncology reports |d 1994 |g 49(2023), 2 vom: 23. Feb. |w (DE-627)NLM09366334X |x 1791-2431 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2023 |g number:2 |g day:23 |g month:02 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3892/or.2022.8468 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2023 |e 2 |b 23 |c 02 | ||